Pharmacy & Therapeutics- August 2008 - (Page 485) CONTINUING EDUCATION CREDIT of migraine with bisoprolol: A placebo-controlled study. Cephalalgia 1997;17:596–599. Diener HC, Hartung E, Chrubasik J. Acetylsalicylic acid in migraine prophylaxis: A double-blind study in comparison with metoprolol. Cephalalgia 1997;17:434. Sargent J, Solbach P, Damasio H, et al. A comparison of naproxen sodium to propranolol hydrochloride and a placebo control for the prophylaxis of migraine headache. Headache 1985;25:320–324. Kozubski W, Prusinski A. Sodium valproate versus propranolol in the prophylactic treatment of migraine. Neurol Neurodur Pol 1995;29:937–947. Kaniecki RG. A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura. Arch Neurol 1997;54:1141–1145. Diener HC, Tfelt-Hansen P, Dahlof C, et al. Topiramate in migraine prophylaxis: Results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004;251(8):943–950. Ashrafi MR, Shabanian R, Zamani GR, et al. Sodium valproate versus propranolol in paediatric migraine prophylaxis. Eur J Paediatr Neurol 2005;9(5):333–338. Corbo J, Esses D, Bijur PE, et al. Randomized clinical trial of intravenous magnesium sulfate as an adjunctive medication for emergency department treatment of migraine headache. Ann Emerg Med 2001;38:621–627. Limmroth V, Michel MC. The prevention of migraine: A critical review with special emphasis on beta-adrenoceptor blockers. Br J Clin Pharmacol 2001;52(3):237–243. Ferrari A, Sternieri E, Ferraris E, Bertolini A. Emerging problems in the pharmacology of migraine: Interactions between triptans and drugs for prophylaxis. Pharmacol Res 2003;48(1):1–9. Goldberg MR, Sciberras D, De Smet M, et al. Influence of betaadrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1b/1d agonist: Differential effects of propranolol, nadolol, and metoprolol. J Clin Pharmacol 2001;52:69–76. Couch JR, Hassanein RS. Amitriptyline in migraine prophylaxis. Arch Neurol 1979;36:695–699. Colombo B, Annovazzi PO, Comi G. Therapy of primar y headaches: The role of antidepressants. Neurol Sci 2004;25 (Suppl 3):S171–S175. Punay NC, Couch JR. Antidepressants in the treatment of migraine headache. Curr Pain Headache Rep 2003;7(1):51–54. Silberstein SD. Preventive treatment of migraine. Trends Pharmacol Sci 2006;27(8):410–415. Gomersall JD, Stuart A. Amitriptyline in migraine prophylaxis: Changes in pattern of attacks during a controlled clinical trial. J Neurol Neurosurg Psychiatry 1973;36:684–690. Ziegler DK, Hurwitz A, et al. Migraine prophylaxis: A comparison of propranolol and amitriptyline. Arch Neurol 1987;44:486–489. King DS, Herndon KC. Headache disorders. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, et al., eds. Pharmacotherapy: A Pathophysiologic Approach. 6th ed. Norwalk, CT: Appleton & Lange; 2005: 1105–1121. Alldredge BK. Neurologic disorders: headache. In: Koda-Kimble MA, Young YL, eds. Applied Therapeutics: The Clinical Use of Drugs, 8th ed. Baltimore: Lippincott Williams & Wilkins; 2005:52-1–52-27. Adly C, Straumanis J, Chesson A. Fluoxetine prophylaxis of migraine. Headache 1992;32(2):101–104. Diamond S, Freitag FG. The use of fluoxetine in the treatment of headache. Clin J Pain 1989;5:200–201. Moja PL, Cusi C, Sterzi RR, et al. Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches. Cochrane Database Syst Rev 2005;(3):CD002919. Gardner DM, Lynd LD. Sumatriptan contraindications and serotonin syndrome. Ann Pharmacother 1998;32:33–38. Shapiro RE, Tepper SJ, et al. The serotonin syndrome, triptans and the potential for drug–drug interactions. Headache 2007;47:266–269. Wooltorton E. Triptan migraine treatment and antidepressants: Risk of serotonin syndrome. Can Med Assoc J 2006;175(8):874. Eadie M. Clinically significant drug interactions with agents specific for migraine attacks. CNS Drugs 2001;15(2):105–118. Goldberg MR, Lowry RC, Musson DG, et al. Lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine. J Clin Pharmacol 1999;39:192–199. 54. Ozyalcin SN, Talu GK, Kiziltan E et al. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 2005;45: 144–152. 55. Bulut S, Berilgen MS, Baran A, et al. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: Randomized double-blind, crossover study. Clin Neurol Neurosurg 2004;107(1): 44–48. 56. Levy E, Margolese HC. Migraine headache prophylaxis and treatment with low-dose mirtazapine. Int Clin Psychopharmacol 2003; 18(5):301–303. 57. Anthony M, Lance JW. Monoamine oxidase inhibition in the treatment of migraine. Arch Neurol 1969;21:263–268. 58. Saper JR, Lake AE, Tepper SJ. Nefazodone for chronic daily headache prophylaxis: An open-label study. Headache 2001;41: 465–474. 59. D’Amico D. Antiepileptic drugs in the prophylaxis of migraine, chronic headache forms, and cluster headache: A review of their efficacy and tolerability. Neurol Sci 2007;28(Suppl 2):S188–S197. 60. Chronicle E, Mulleners W. Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst Rev 2004;(3):CD003226. 61. Calabresi P, Galletti F, Rossi C, et al. Antiepileptic drugs in migraine: From clinical aspects to cellular mechanisms. Trends Pharmacol Sci 2007;28(4):188–195. 62. Sorensen KV. Valproate: A new drug in migraine prophylaxis. Acta Neurol Scand 1988;78:346–348. 63. Gallagher RM, Mueller LL, Freitag FG. Divalproex sodium in the treatment of migraine and cluster headaches. J Am Osteopath Assoc 2002;102(2):92–94. 64. Freitag FG, Collins SD, Carlson HA, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002;58:1652–1659. 65. Freitag FG. Divalproex in the treatment of migraine. Psychopharmacol Bull 2003;37(Suppl 2):98–115. 66. Kinze S, Clauss M, Reuter U, et al. Valproic acid is effective in migraine prophylaxis at low serum levels: A prospective open-label study. Headache 2001;41:774–778. 67. Lenaerts M, Bastings E, Sianard J. et al. Sodium valproate in severe migraine and tension-type headache: An open-label study of long-term efficacy and correlation with blood levels. Acta Neurol Belg 1996;96:126–129. 68. McNamara JO. Drugs effective in the therapy of epilepsies. In: Gilman AG, Hardmen JG, Limbird LE, eds. Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 10th ed. Elmsford, NY: Pergamon Press, 2001:521–547. 69. Storey JR, Calder CS, Hart DE, et al. Topiramate in migraine prevention: A double-blind placebo-controlled study. Headache 2001; 41:968–975. 70. Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: A randomized controlled trial. JAMA 2004;291(8): 965–973. 71. Peres MF, Mercante JP, Tanuri FC, et al. Chronic migraine prevention with topiramate. Headache 2006;7(4):185–187. 72. Li HL, Kwan P, Leung H, et al. Topiramate for migraine prophylaxis among Chinese populations. Headache 2007;47(4):616–619. 73. Diener HC, Bussone G, Van Oene JC, et al. Topiramate reduces headache days in chronic migraine: A randomized, double-blind, placebo-controlled study. Cephalalgia 2007;27(7):814–823. 74. Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: A randomized, double-blind, placebo-controlled trial. Headache 2007;47(2): 170–180. 75. Rapoport A, Mauskop A, Diener HC, et al. Long-term migraine prevention with topiramate: Open-label extension of pivotal trials. Headache 2006;46(7):1151–1160. 76. Silberstein SD, Feliu AL, Rupnow MF, et al. Topiramate in migraine prophylaxis: Long-term impact on resource utilization and cost. Headache 2007;47(4):500–510. 77. Bussone G, Diener HC, Pfeil J, et al. Topiramate 100 mg/day in migraine prevention: A pooled analysis of double-blind randomized trials. Int J Clin Pract 2005;59(8):961–968. 78. Winner P, Gendolla A, Stayer C, et al. Topiramate for migraine prevention in adolescents: A pooled analysis of efficacy and safety. Headache 2006;46(10):1503–1510. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. Vol. 33 No. 8 • August 2008 • P&T® 485
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.